Find Drugs for Pulmonary/Respiratory Diseases in Phase II Clinical Development in UNITED STATES

Lead Product(s): Mometasone Furoate

Therapeutic Area: Pulmonary/Respiratory Diseases

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Perceptive Advisors

Deal Size: $30.0 million Upfront Cash: Undisclosed

Deal Type: Series C Financing January 29, 2020

Details:

Lyra plans to use the proceeds for the advancement of the company’s lead product candidates, LYR-210 and LYR‑220, and for general corporate purposes.

Lead Product(s): Sodium Fusidate

Therapeutic Area: Pulmonary/Respiratory Diseases

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 28, 2020

Details:

ARV-1801 is one of the very few oral antibiotics that has increased potency in low pH environments and also has anti-inflammatory activity.

Lead Product(s): Sotatercept

Therapeutic Area: Pulmonary/Respiratory Diseases

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 27, 2020

Details:

The PULSAR trial achieved its primary endpoint: a statistically significant reduction in pulmonary vascular resistance

Lead Product(s): Tipelukast

Therapeutic Area: Pulmonary/Respiratory Diseases

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 27, 2020

Details:

The allowed claims cover the use of MN-001 for treating a patient diagnosed with idiopathic pulmonary fibrosis.

Lead Product(s): MultiStem cell therapy

Therapeutic Area: Pulmonary/Respiratory Diseases

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 14, 2020

Details:

One-year results support positive 28-day findings and suggest further benefits for ARDS patients.

Lead Product(s): Levosimendan

Therapeutic Area: Pulmonary/Respiratory Diseases

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 13, 2020

Details:

Tenax Therapeutics reports that till now 24 patients have been randomized, pulmonary capillary wedge pressure was reduced and no serious drug-related adverse events have been reported to date.

Lead Product(s): Sirolimus

Therapeutic Area: Pulmonary/Respiratory Diseases

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 07, 2020

Details:

The company has made significant recent progress on its four clinical assets and proprietary Guardian Angelâ„¢ algorithm.